Hvilken er prisen på Vertex Pharmaceuticals Incorporated (VRTX)

Prisen på Vertex Pharmaceuticals Incorporated (VRTX) er $519.38

Hva er markedsverdien på Vertex Pharmaceuticals Incorporated (VRTX)

Markedsverdien på Vertex Pharmaceuticals Incorporated (VRTX) er $131.82B

Vertex Pharmaceuticals Incorporated (VRTX) P/B-forhold

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

År	P/B-forhold	Endre
2026 (TTM)	6.83	8.04%
2024	6.32	5.95%
2023	5.96	12.20%
2022	5.32	-5.13%
2021	5.60	-20.74%
2020	7.07	-23.47%
2019	9.24	-2.78%
2018	9.50	-48.32%
2017	18.38	18.49%
2016	15.52	-51.87%
2015	32.24	24.19%
2014	25.96	110.80%
2013	12.32	38.57%
2012	8.89	2.78%
2011	8.65	-37.92%
2010	13.93	105.70%
2009	6.77	-62.12%
2008	17.88	61.85%
2007	11.04	31.89%
2006	8.37	-18.89%
2005	10.32	-55.94%
2004	23.43	467.01%
2003	4.13	30.31%
2002	3.17	-17.67%
2001	3.85	-59.09%
2000	9.41	0.00%

År

P/B-forhold

Endre

2026 (TTM)

6.83

8.04%

2024

6.32

5.95%

2023

5.96

12.20%

2022

5.32

-5.13%

2021

5.60

-20.74%

2020

7.07

-23.47%

2019

9.24

-2.78%

2018

9.50

-48.32%

2017

18.38

18.49%

2016

15.52

-51.87%

2015

32.24

24.19%

2014

25.96

110.80%

2013

12.32

38.57%

2012

8.89

2.78%

2011

8.65

-37.92%

2010

13.93

105.70%

2009

6.77

-62.12%

2008

17.88

61.85%

2007

11.04

31.89%

2006

8.37

-18.89%

2005

10.32

-55.94%

2004

23.43

467.01%

2003

4.13

30.31%

2002

3.17

-17.67%

2001

3.85

-59.09%

2000

9.41

0.00%

Selskap	P/B-forhold	Forskjell i P/B-forhold	Land
Argenx SE ARGX.US	7.5116	10.01%	NL
CSL Limited CSL.AX	3.9942	-41.50%	AU
Moderna, Inc. MRNA.US	8.2199	20.39%	US
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	3.5101	-48.59%	BE

Selskap

P/B-forhold

Forskjell i P/B-forhold

Land